Patents by Inventor Christoph Spiess

Christoph Spiess has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11434482
    Abstract: The invention provides methods of identifying bacteria comprising binding polypeptides. The invention also provides methods of identifying bacteria with improved expression of binding polypeptides. The invention also provides methods of identifying binding polypeptides with improved expression. The invention also provides engineered bacteria suitable for use in the methods of the invention. The invention also provides compositions that can be obtained using the methods, for example, anti-interleukin-13 (IL-13) antibodies with improved expression and/or stability. The invention also provides libraries comprising binding polypeptide (e.g., antibody) variants.
    Type: Grant
    Filed: October 12, 2017
    Date of Patent: September 6, 2022
    Assignee: Genentech, Inc.
    Inventors: Twyla Noelle Lombana, Rebekah McKenna, Christoph Spiess, Karthik Veeravalli, Michael Dillon
  • Publication number: 20220064331
    Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.
    Type: Application
    Filed: June 8, 2021
    Publication date: March 3, 2022
    Applicant: GENENTECH, INC.
    Inventors: Yongmei Chen, James Ernst, Hok Seon Kim, Junichiro Sonoda, Christoph Spiess, Scott Stawicki, Yan Wu
  • Publication number: 20220048993
    Abstract: The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.
    Type: Application
    Filed: October 29, 2021
    Publication date: February 17, 2022
    Inventors: Isidro HOTZEL, Teemu T. JUNTTILA, Ji LI, Justin SCHEER, Danielle DICARA, Diego ELLERMAN, Christoph SPIESS, Paul J. CARTER
  • Publication number: 20220048990
    Abstract: The presently disclosed subject matter provides antibodies, e.g., IgA antibodies and IgG-IgA fusion molecules, and compositions comprising such antibodies, as well as methods of making and using such antibodies and compositions.
    Type: Application
    Filed: July 20, 2021
    Publication date: February 17, 2022
    Applicant: GENENTECH, INC.
    Inventors: Twyla Noelle Lombana, Julie A. Zorn, Marissa L. Matsumoto, Christoph Spiess, Claudio Ciferri, Alberto Estevez
  • Patent number: 11192950
    Abstract: The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.
    Type: Grant
    Filed: April 25, 2019
    Date of Patent: December 7, 2021
    Assignee: Genentech, Inc.
    Inventors: Isidro Hotzel, Teemu T. Junttila, Ji Li, Justin Scheer, Danielle Dicara, Diego Ellerman, Christoph Spiess, Paul J. Carter
  • Patent number: 11116840
    Abstract: Provided are, inter alia, multispecific antigen binding proteins, or antigen-binding fragments thereof, comprising one or more mutations in the VH/VL domains and/or CH1/CL domains, pharmaceutical compositions comprising same, isolated nucleic acids, vectors, and host cells encoding/expressing same, method of making the multispecific antigen binding proteins, computer readable media for evaluating multispecific antigen binding proteins, and libraries.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: September 14, 2021
    Assignee: Genentech, Inc.
    Inventors: Paul Carter, Christoph Spiess, Yiyuan Yin, Jianhui Zhou, Wendy Sandoval, Jacob Corn, Michael Dillon
  • Publication number: 20210179715
    Abstract: Provided herein are anti-Ly6G6D (lymphocyte antigen 6 complex, locus G61) antibodies and methods of using the same.
    Type: Application
    Filed: December 11, 2020
    Publication date: June 17, 2021
    Inventors: WeiYu LIN, Christoph SPIESS, Liping SUN, Yan WU, Cecilia P.C. CHIU, Walter Christian DARBONNE, Michael Andrew DILLON
  • Publication number: 20210171662
    Abstract: Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.
    Type: Application
    Filed: September 18, 2020
    Publication date: June 10, 2021
    Inventors: Justin SCHEER, Christoph SPIESS, Daniel G. YANSURA
  • Patent number: 10882921
    Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: January 5, 2021
    Assignee: GENENTECH, INC.
    Inventors: Yongmei Chen, James Ernst, Hok Seon Kim, Junichiro Sonoda, Christoph Spiess, Scott Stawicki, Yan Wu
  • Publication number: 20200308304
    Abstract: The instant disclosure provides antibody fragments (e.g., Fab and F(ab?)2) having reduced or no reactivity towards pre-existing anti-hinge antibodies (AHA) and compositions comprising such antibody fragments, as well as methods of making and using such antibody fragments and compositions.
    Type: Application
    Filed: April 17, 2020
    Publication date: October 1, 2020
    Applicant: GENENTECH, INC.
    Inventors: Yu-Ju G. Meng, Hok Seon Kim, Ingrid Kim, Christoph Spiess
  • Patent number: 10662254
    Abstract: The instant disclosure provides antibody fragments (e.g., Fab and F(ab?)2) having reduced or no reactivity towards pre-existing anti-hinge antibodies (AHA) and compositions comprising such antibody fragments, as well as methods of making and using such antibody fragments and compositions.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: May 26, 2020
    Assignee: Genentech, Inc.
    Inventors: Yu-Ju G. Meng, Hok Seon Kim, Ingrid Kim, Christoph Spiess
  • Publication number: 20200055939
    Abstract: The invention provides anti-MIC antibodies and methods of using the same.
    Type: Application
    Filed: October 27, 2017
    Publication date: February 20, 2020
    Applicant: Genentech, Inc.
    Inventors: Twyla Noelle LOMBANA, Christoph SPIESS, Jeong KIM, Evangeline TOY, Jill SCHARTNER, Zhengmao YE, Jack BEVERS, III, Ryan COOK, Marissa MATSUMOTO, Amy BERKLEY
  • Publication number: 20190315860
    Abstract: The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.
    Type: Application
    Filed: April 25, 2019
    Publication date: October 17, 2019
    Inventors: Isidro HOTZEL, Teemu T. JUNTTILA, Ji LI, Justin SCHEER, Danielle DICARA, Diego ELLERMAN, Christoph SPIESS, Paul J. CARTER
  • Publication number: 20190270814
    Abstract: The present invention provides bispecific antigen-binding molecules having a monovalent arm specific to a first target antigen (e.g., a T cell antigen, such as CD3) and a bivalent arm specific for a second target antigen (e.g., a tumor antigen, such as HER2). Bispecific antigen-binding molecules are useful in the treatment of disorders, such as cancer (e.g., HER2-positive cancer). The invention also features methods of producing bispecific antigen-binding molecules, methods of treating disorders using bispecific antigen-binding molecules, and compositions including bispecific antigen-binding molecules.
    Type: Application
    Filed: February 8, 2019
    Publication date: September 5, 2019
    Inventors: Diego ELLERMAN, Teemu T. JUNTTILA, Twyla Noelle LOMBANA, Dionysos SLAGA, Christoph SPIESS
  • Publication number: 20190185584
    Abstract: Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.
    Type: Application
    Filed: July 25, 2018
    Publication date: June 20, 2019
    Inventors: Justin SCHEER, Christoph SPIESS, Daniel G. YANSURA
  • Patent number: 10323094
    Abstract: The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: June 18, 2019
    Assignee: Genentech, Inc.
    Inventors: Isidro Hotzel, Teemu T. Junttila, Ji Li, Justin Scheer, Danielle DiCara, Diego Ellerman, Christoph Spiess, Paul J. Carter
  • Publication number: 20190177432
    Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.
    Type: Application
    Filed: February 25, 2019
    Publication date: June 13, 2019
    Applicant: GENENTECH, INC.
    Inventors: Yongmei Chen, James Ernst, Hok Seon Kim, Junichiro Sonoda, Christoph Spiess, Scott Stawicki, Yan Wu
  • Patent number: 10246518
    Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: April 2, 2019
    Assignee: Genentech, Inc.
    Inventors: Yongmei Chen, James Ernst, Hok Seon Kim, Junichiro Sonoda, Christoph Spiess, Scott Stawicki, Yan Wu
  • Publication number: 20190040142
    Abstract: The presently disclosed subject matter relates to multispecific antibodies, e.g., bispecific antibodies and biepitopic antibodies, and methods for screening for such antibodies, and a novel antibody structure that can be used to screen for such bispecific antibodies and biepitopic antibodies.
    Type: Application
    Filed: May 8, 2018
    Publication date: February 7, 2019
    Applicant: GENENTECH, INC.
    Inventors: Diana Ronai Dunshee, Joanne Hongo, Hok Seon Kim, Junichiro Sonoda, Christoph Spiess, Angie Grace Yee
  • Publication number: 20180305462
    Abstract: The instant disclosure provides antibody fragments (e.g., Fab and F(ab?)2) having reduced or no reactivity towards pre-existing anti-hinge antibodies (AHA) and compositions comprising such antibody fragments, as well as methods of making and using such antibody fragments and compositions.
    Type: Application
    Filed: April 30, 2018
    Publication date: October 25, 2018
    Applicant: GENENTECH, INC.
    Inventors: Yu-Ju G. Meng, Hok Seon Kim, Ingrid Kim, Christoph Spiess